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ABSTRACT
Despite the use of clinical prognostic factors (PSA, T-category and Gleason 
score), 20-60% of localized prostate cancers (PCa) fail primary local treatment. 
Herein, we determined the prognostic importance of main sensors of the DNA 
damage response (DDR): MRE11A, RAD50, NBN, ATM, ATR and PRKDC. We studied 
copy number alterations in DDR genes in localized PCa treated with image-guided 
radiotherapy (IGRT; n=139) versus radical prostatectomy (RadP; n=154). In both 
cohorts, NBN gains were the most frequent genomic alteration (14.4 and 11% of 
cases, respectively), and were associated with overall tumour genomic instability 
(p<0.0001). NBN gains were the only significant predictor of 5yrs biochemical relapse-
free rate (bRFR) following IGRT (46% versus 77%; p=0.00067). On multivariate 
analysis, NBN gain remained a significant independent predictor of bRFR after 
adjusting for known clinical prognostic variables (HR=3.28, 95% CI 1.56–6.89, 
Wald p-value=0.0017). No DDR-sensing gene was prognostic in the RadP cohort. In 
vitro studies correlated NBN gene overexpression with PCa cells radioresistance. In 
conclusion, NBN gain predicts for decreased bRFR in IGRT, but not in RadP patients. 
If validated independently, Nibrin gains may be the first PCa predictive biomarker to 
facilitate local treatment decisions using precision medicine approaches with surgery 
or radiotherapy.
INTRODUCTION
Men with localized prostate cancer (PCa) are 
categorized in risk groups that reflect increasing 
treatment failure rates and prostate cancer specific 
mortality (e.g. low, intermediate or high) on the basis 
of pathologic Gleason score (GS), pre-treatment serum 
prostate specific antigen (PSA, measured in ng/mL) and 
clinical T-category (TNM staging system) [1-2]. Despite 
clinical classification, intermediate and high-risk PCa are 
characterized by significant heterogeneity with respect to 
clinical outcome after image-guided radiotherapy (IGRT) 
or radical prostatectomy, with biochemical relapse-free 
rates (bRFR) ranging from 40 to 80% [3]. This suggests 
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that other pathologic, genomic or molecular factors could 
further triage patients into responders and non-responders 
by developing novel prognostic (treatment-independent) 
or predictive (treatment-dependent) biomarkers. 
Malignant progression to the metastatic state is 
associated with increasing oncogene activation, tumor 
suppressor gene inactivation and increased genomic 
instability [4]. These genetic alterations may accumulate 
due to abnormal DNA damage responses (DDR) in the 
sensing and repair of DNA damage [5-6]. An abnormality 
in the DDR pathway could lead to cancer progression 
and metastases and/or affect the relative sensitivity of a 
tumour to radiotherapy, in which daily doses of photon 
radiation lead to DNA double-strand breaks (DSBs), 
and other DNA damages. Indeed, in vitro experiments 
support the hypothesis that differential prostate cancer 
cell radiosensitivity and genetic instability are correlated 
to differential DDR integrity [7-8].
The earliest and fundamental step in the process 
of the DDR is the recruitment of sensing and repair 
machinery to the sites of DNA damage [9]. The initial 
protein effectors of the DDR are the MRN complex 
(MRE11, RAD50 and NBS-1/Nibrin encoded by the 
MRE11A, RAD50 and NBN genes, respectively) and the 
DNA damage dependent, PI3-like kinases: ATM, ATR and 
DNA-PKcs (encoded by the ATM, ATR and PRKDC genes, 
respectively). ATM and NBN mutations have also been 
suggested to confer increased risk of prostate cancer [10-
11] and disease aggression [12-13]. To date, a systematic 
analysis of copy number alterations (CNAs) within the 
initial DDR sensor genes (MRE11A, RAD50, NBN, ATM, 
ATR, PRKDC) as potential prognostic biomarkers has not 
been explored. 
Herein, we collated the alterations in DDR sensors 
within localized prostate cancer, and show that copy 
number gains in the NBN locus is a novel adverse and 
independent factor for outcome following radiotherapy, 
but not following radical prostatectomy, in localized PCa. 
We discuss the use of NBN status to intensify therapy in 
the context of personalized PCa medicine. 
RESULTS
CNAs of DDR genes are common in localized PCa
We initially determined whether DDR-sensing 
genes (MRE11A, RAD50, NBN, ATM, ATR and PRKDC) 
exhibited allelic gains or losses in our cohort. Upon 
evaluation of 139 pre-IGRT biopsies by aCGH, allelic 
changes were observed predominantly in NBN (15.1%), 
ATR (8.6%), PRKDC (7.9%) and ATM (5.8%). The 
surgical cohort showed a similar proportion of allelic 
Figure 1: Heatmap of CNAs in DDR genes in tumour biopsies from the IGRT (1A) or RadP (1B) cohorts. Each bar 
represents a single patient. Gains and losses are represented by red and blue bars, respectively. 
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changes in the NBN (11.6%) and ATM (6.5%) loci but 
higher in PRKDC (14.9%) and lower in ATR (1.3%) 
loci. RAD50 and MRE11A showed less than 5% of 
aberrations within each cohort (see Figures 1A/B). CNA 
distributions in these six DDR genes were not statistically 
different across any of the clinical prognostic variables of 
pretreatment PSA, T-category and GS (data not shown). 
To determine how hits within the DDR sensor genes 
relate to each other, we explored the co-segregation and 
mutual exclusivity patterns of allelic changes in these 
six loci. To increase statistical power, we combined both 
treatment cohorts (pooled cohort) for this analysis. Five 
gene-pairs were co-altered in more patients than expected 
by chance (Fisher’s exact test, p < 0.001, Bonferroni 
correction): ATM-ATR, ATM-MRE11A, NBN-ATM, 
NBN-ATR and NBN-PRKDC (Supplemental Figure 1). 
No aberrations in DDR-sensing genes were mutually 
exclusive. We conclude that ATM and NBN alterations can 
associate with the other DDR alterations in PCa. 
Patients with NBN CNAs show increased genomic 
instability
Considering that DDR genes play a role in genomic 
integrity, we used the percent genome aberration (PGA) to 
describe the instability within a patient’s tumour genome. 
NBN exhibited the strongest association of a DNA 
damage response-sensing gene with PGA in both RadP 
and IGRT cohorts (see Figure 2). Using the pooled cohort, 
CNAs in all six DDR-sensing genes remained significantly 
correlated with higher PGA, independent of the clinical 
prognostic variables (pretreatment PSA, T-category and 
GS) (Supplemental Table 1).
Table 1: Clinical characteristics of IGRT and RadP cohorts
IGRT cohort RadP cohort How was used in the analysis
N=139 (%) N=154 (%)
T-category
    T1
    T2
    T3
50 (36%)
89 (64%)
-
79 (51.3%)
66 (42.9%)
9 (5.8%)
T1 vs T2-T3
Gleason-score
   5
   6
   7
   8
   9
-
34 (24.4%)
98 (70.5%)
7 (5%)
-
2 (1.3%)
82 (53.3%)
53 (34.4%)
11 (7.1%)
6 (3.9%)
GS 5-6 vs 7-9
Pretreatment-PSA (ng/mL)
    Median
    Range
    <10
    10-20
    >20
8.0
0.9 – 33
92 (66.2%)
41 (29.5%)
6 (4.3%)
6.265
1.15 – 506
115 (74.7%)
24 (15.6%)
15 (9.7%)
PSA <10 vs > 10
NCCN Risk Group 
(Clinical staging)
   Low
   Intermediate
   High
19 (13.6%)
107 (77.0%)
13 (9.4%)
45 (29.2%)
79 (51.3%)
30 (19.5%)
-
Hormone therapy
   Neo-adjuvant 35 (25.2%) 7 (4.5%) -
RT dose (Gy/fraction)
   60/20
   66/22
   70/35
   75.6/42
   78/39
   79.8/42
Mean equivalent dose= 75.9Gy
15 (10.8%)
3   (2.1%)
1 (0.7%)
38 (27.3%)
3   (2.1%)
79 (56.8%)
NA -
BCR (5yrs)
   Yes
   No
34 (24.5%)
105 (75.5%)
34 (22.1%)
120 (77.9%) -
Abbreviations: Gy=Gray, IGRT=image guided radiotherapy, BCR=biochemical recurrence, NA=not 
applicable. Mean RT equivalent dose was calculated using BED formula at 2 Gy daily fractions with 
an alpha/beta ratio of 2.0 for tumor response.
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Patients with CNAs in DDR genes are more likely 
to relapse after IGRT
We next examined the impact of allelic changes in 
the DDR loci on clinical outcome based on biochemical 
recurrence (BCR). The clinical characteristics the IGRT 
cohort are shown in Table 1. At five years, 34 patients 
(24.5%) experienced biochemical failure as per the 
Phoenix definition. In this predominantly intermediate-risk 
group cohort, only PSA remained as a significant clinical 
prognostic factor for BCR based on univariate analysis 
(p-value = 0.0035) (see Supplemental Figure 2A). We 
tested DDR genes CNAs (gains or losses) for prognostic 
capability. Only NBN was prognostic for bRFR at 5 years 
on univariate analysis (bRFR 46% vs. 77%, log-rank 
p-value = 0.00067; HR= 3.35; 95% CI: 1.6 – 7.01; see 
Figure 3A). On multivariate analysis, NBN gains remained 
a significant independent predictor of bRFR after adjusting 
for PSA, T-category and GS (HR = 3.28, 95% CI 1.56 
– 6.89, Wald p-value = 0.0017; see Table 2). NBN gains 
remained a significant predictor of bRFR even within low-
risk patients (log rank p-value = 0.0037; Supplemental 
Figure 3); although the number of low-risk patients with 
NBN gains is low (4 patients). 
We next interrogated the surgically treated RadP 
cohort (n=154). At five years after surgery, thirty-four 
Figure 2: PGA as a function of DDR genes copy number status for IGRT and RadP cohorts. Each dot represents an 
individual patient with black, red and blue dots representing copy number neutral, loss, or gain respectively. The horizontal black line 
denotes the median PGA for each group. In both the IGRT and RadP cohorts, DDR genes CNAs associate with increased genomic instability 
(PGA) compared to patients with copy number neutral DDR gene status (p-values are shown; Mann-Whitney-U-test).
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patients (22.1%) experienced biochemical failure. All three 
known clinical prognostic variables remained significant 
predictors of biochemical outcome (Supplemental Figure 
2B). On univariate analysis, NBN gain did not have 
significant prognostic value (HR = 1.88, 95% CI 0.78 
– 4.54, log-rank p-value = 0.15) (see Figure 3B). To 
further evaluate the potential prognostic role of NBN in 
this cohort, we explored the impact of mRNA abundance 
and its known partner KPNA2 on treatment outcome. In 
the 108 RadP patients with matched CNA and mRNA 
information, we found a significant association between 
NBN copy-number gain and NBN mRNA abundance 
(Student’s t-test, p-value = 0.0074; Supplemental Figure 
4A). However, neither NBN nor KPNA2 mRNA abundance 
(stratified by median expression) correlated with bRFR 
(Supplemental Figure 4B/C). 
Finally, we evaluated whether NBN gains added 
clinical value to the standard prognostic variables 
(PSA, T-category and GS) in our IGRT cohort using 
concordance-index (c-statistic), net reclassification index 
(NRI) and integrated discrimination improvement (IDI) 
(see ‘statistical analysis’ methods). The c-statistic of the 
clinical model (0.645, 95% CI 0.528-0.761) improved 
with the addition of NBN gains (0.673, 95% CI 0.562-
0.785), indicating that the addition of NBN provides 
some improvement to the basic clinical model for 
predicting patient outcome. Similarly, the model including 
NBN assigned a higher risk to 28.5% of patients who 
experienced a BCR compared to the model without NBN; 
while the addition of NBN assigned a higher risk to 10.0% 
of patients censored at 5 years compared to the model 
without NBN. The net difference or NRI was therefore 
18.5% (95% CI -1.7 – 36.5%, p-value = 0.11). It is also 
interesting that the average sensitivity of the model with 
NBN improved 5.0% from the basic clinical model, while 
the average specificity of the model increased marginally 
1.4%. The integrated discrimination improvement (IDI), 
or net improvement in these quantities showed significant 
improvement at 6.45% (95% CI: 0.4% - 17.6%, p-value 
= 0.027). These three methods indicate that knowing 
the NBN status of a patient can be used to better predict 
biochemical failure following IGRT (see Supplemental 
Table 2).
NBN status and expression associates with 
radioresistance in vitro
Given the potential additional role of NBN gains 
as a predictive factor for outcome after IGRT, we 
determined the correlation between absolute DDR gene 
mRNA expression and intrinsic clonogen radioresistance 
in a panel of prostate cell lines (see Supplemental Figure 
Figure 3: Kaplan-Meier plots of bRFR versus time to recurrence showing the effect of differential NBN CNA status 
(neutral vs. gain) in the IGRT (3A) or RadP (3B) treatment cohorts.
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5). Of the six DDR genes, only NBN gene expression 
showed a positive correlation with increasing clonogen 
radioresistance (e.g. increasing SF3Gy; r
2 = 0.871, p-value 
of slope = 0.066; see Figure 4). This data suggest a role for 
NBN gains in intrinsic tumour resistance to radiotherapy, 
consistent with its poor prognostic impact in IGRT-treated 
patients. 
DISCUSSION
To our knowledge, this is the first study to describe 
the frequency and importance of alterations in genes that 
are initial sensors within the DDR pathways within PCa 
patients. We particularly were interested in the potential 
effect of abnormalities in genes involved in the initial DNA 
damage response-sensing for IGRT patients who receive 
daily doses of DNA DSBs as part of their treatment. Our 
main finding, that an altered DDR is predictive for IGRT 
outcome, is important given our results are based on a 
genomic test using pre-treatment biopsies which are used 
to direct primary management decisions of localized PCa. 
This prognostic effect was not observed in surgery patients 
in whom DDR responses are probably irrelevant. 
If our IGRT-based observation with NBN gains is 
validated in other independent and/or large prospective 
cohorts using aCGH or FISH (fluorescence in situ 
hybridization, using a NBN-specific probe), this could 
become the first predictive test for selecting patients to 
undergo surgery (rather than IGRT alone) or undergo 
IGRT treatment intensification (e.g. further radiotherapy 
dose-escalation or the additional use of systemic agents). 
We confirmed our hypothesis that aberrations in 
DDR genes would associate with unstable PCa genomes. 
At present, it is not known whether NBN gains, are drivers 
or passengers within PCa progression. It should be noted 
that the NBN locus in on chromosome 8q which is one 
of the most altered areas of the genome in our patient 
cohort, and therefore NBN gains may strongly relate to 
other gene loci abnormalities (e.g. c-Myc). We cannot 
yet conclude that NBN’s effect is gene-specific (e.g. 
prognostic at the mRNA and/or protein level) or rather a 
reflection of an important role as a surrogate of genomic 
instability; results from ongoing multimodal genomic 
studies (ICGC and TCGA consortia) may help clarify 
NBN gains linkage to specific CNAs, mutations or gene 
rearrangements. Furthermore, a recent publication form 
the TCGA consortia in colorectal cancer has shown that 
many CNA-driven increases in mRNA levels do not 
translate into greater abundance of the corresponding 
protein [14]. Future research is required to characterize 
NBN gains functional effect in the DDR of PCa tumours.
Based on previous work suggesting that germline 
NBN mutations predispose to more aggressive phenotypes 
of disease [13], we speculate that failures in IGRT-treated 
patients could be related to radioresistance and increased 
NBN-associated genomic instability that leads to greater 
capacity for micrometastatic spread. Neither NBN gain 
nor NBN mRNA expression (or expression of its partner, 
KPNA2) was prognostic in the surgery cohort; consistent 
with previous publications on Nibrin expression in 
surgically treated prostate cancer patients [15-16]. The 
only current predictive DDR biomarker for radiotherapy 
response is MRE11 protein expression in bladder cancer 
[17], which has been independently validated [18]. 
However, MRE11A alterations were not frequent (nor 
prognostic) in our PCa cohorts. 
We acknowledge a number of limitations to the 
current study. First, our biomarker and outcome analyses 
are based on a single TRUS-guided biopsy to the dominant 
lesion; therefore the known intraprostatic heterogeneity 
Figure 4: Normalized NBN mRNA abundance plotted against relative radioresistance (clonal surviving fraction after 
3 Gy; SF3Gy) . Linear regression (continuous line) and 95% confidence interval (doted lines) are shown. A correlation is observed 
(R-square = 0.871) with a significant trend in the p-value of the slope (p=0.066). For PrEC cell line, only clonogenic survival fraction after 
2Gy (SF2Gy) was available, therefore it was not included in the linear regression calculation. 
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and differential biology of multifocal disease might be 
underestimated [19]. However, the biopsies were taken 
from the dominant (index) lesion in each patient, which 
usually correlates with the majority of local treatment 
failures [20]. Also, our radiotherapy and surgical cohorts 
differ slightly in the distribution of clinical prognostic 
features and duration of follow-up, which could reduce 
the power to detect significant results in the DNA-based 
prognosis analyses for the surgical cohort. However, as 
stated above, protein expression for NBN is not prognostic 
in other surgical series [15-16].
In conclusion, our study suggests that gain of NBN 
is a potentially novel predictive factor of IGRT failure, and 
patients should consider surgery if their tumour harbours 
this CNA. If validated, this would be the first outcome-
associated predictive biomarker for local treatment in 
localized PCa. IGRT patients whose tumours harbour NBN 
gains should be assessed for additional systemic therapies 
to improve outcome [21].
MATERIALS AND METHODS 
Study Patient Cohorts
DNA samples for array comparative genomic 
hybridization (aCGH) analysis were derived from pre-
treatment frozen biopsies in patients undergoing radical 
image-guided radiotherapy (REB#00-0443-C; the Princess 
Margaret Cancer Centre), as previously described [22]. 
The clinical target volume (CTV) encompassed the 
prostate gland alone. The planning target volume (PTV) 
was defined by a 10 mm expansion around the CTV 
except posteriorly in which the margin was 7 mm. All 
patients were treated with 6-field conformal or intensity 
modulated image-guided radiotherapy. The radiotherapy 
dose was escalated over the period of accrual in a series 
of separate Phase I-II studies (see Table 1). Some patients 
received short-term, neoadjuvant and concurrent anti-
androgen treatment (bicalutamide 150 mg po od). None 
of the patients received LHRH agonists/antagonists nor 
adjuvant androgen deprivation therapy. Staging bone 
scans and computed tomography (CT) were not routinely 
carried out on low- and intermediate-risk disease patients. 
Patients were followed at 4-6 monthly intervals after 
completing treatment with clinical examination and PSA 
measurement. Additional tests and the management of 
patients with recurrent disease were at the discretion of 
the treating physician.
Sufficient tumour for aCGH analysis was identified 
in 139 patients who also had long term follow-up 
information pertaining to biochemical outcome (see Table 
1). The median follow-up of surviving patients was 7.9 
years following the start of treatment, with 62 (44.6%) 
patients experiencing biochemical failure during follow-
up. 
We interrogated the publicly-available Memorial 
Sloan Kettering Cancer Center Prostate Cancer database 
[23] for aCGH data pertaining to 154 PCa tumours of 
patients treated by radical prostatectomy (RadP). Gene-
level CNA calls were collapsed to losses or gains. Patients 
were placed into low-, intermediate-, and high-risk NCCN 
categories [2] based on pre-surgery clinical staging. (see 
Table 1). The median follow-up for this cohort was 4.8 
years, with 38 patients (24.7%) experiencing biochemical 
failure during the entire follow-up. For selected RadP 
cohort patients (108 out of 154), we also used this 
database to compare mRNA abundance to allelic gain or 
loss in DDR genes. 
Array Comparative Genomic Hybridization 
(aCGH) for CNA Calls 
For the IGRT cohort, DNA extraction, labeling and 
hybridization onto arrays containing 26,819 bacterial 
artificial chromosome (BAC)-derived amplified fragment 
pools was carried out as described previously [24]. 
The resulting data set was normalized using a stepwise 
normalization procedure [25]. This data is available in 
NCBI’s Gene Expression Omnibus with accession number 
GSE41120. Areas of aberrant copy number were identified 
using a robust Hidden Markov Model [26] and classified 
as either loss, neutral or gain for all clones. The liftOver 
tool from UCSC was used to map the copy number 
segments to the hg19 human genome build. Fragments 
overlapping centromeres, telomeres, or other gaps in the 
hg18 build were trimmed conservatively (regions were 
shortened rather than elongated). To generate contiguous 
CNA regions, probe-based CNA calls were collapsed 
with neighbouring probes within the same chromosome 
with the same copy number. CNA regions with only 
one supporting probe were removed. In addition, any 
CNAs found entirely within centromeres or telomeres, 
as defined by the UCSC ‘gap’ table, were removed. CNA 
regions were intersected with a merged and collapsed 
version of the RefSeq gene annotation (GRCh37/hg19) to 
generate gene-based CNA calls. This gene list was further 
filtered to match the published gene list from the radical 
prostatectomy (RadP) cohort (n = 17,603).
For both IGRT and RadP cohorts, percent genome 
aberration (PGA) was used as a measure of genomic 
instability and defined as the cumulative size of the genetic 
alterations found in each patient DNA sample divided by 
the total size of the human genome as previously described 
[27]. To account for the fact that a gene may be found 
in a large aberration (which can skew PGA values), we 
removed chromosomal effects from PGA-association 
calculations for each gene. For example, for MRE11A 
(which is on chromosome 11), we calculated PGA using 
chromosomes 1-10 and 12-22 only. Thus, if MRE11A is 
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truly associated with PGA, the effect should be observed 
throughout the genome and unaffected by this adjustment. 
The raw PGA and the adjusted-PGA are highly correlated 
(Supplemental Figure 6) and as such, we show adjusted-
PGA values throughout the manuscript.
mRNA Expression and In Vitro Radiosensitivity 
Assays 
To corroborate the findings at the CNA level in the 
surgery cohort, mRNA abundance data for the RadP cohort 
was also considered for candidate genes. We focused on 
the 108 patients with primary disease that were previously 
studied at the mRNA and CNA level [23]. Raw CEL files 
were downloaded from GEO (accession GSE21034) and 
normalized with RMA [28], as previously described [29]. 
Clonogenic assay data on radiation surviving 
fraction at 3Gy (SF3Gy) for PCa cells (PrEC, LNCaP, 
22RV1, PC-3, and DU-145) were determined as previously 
published[22]. All cell lines were obtained from American 
Type Culture Collection and authenticated by short 
tandem repeat DNA profiling. Nuclear and cytoplasmic 
RNA was extracted and assayed with the NanoString 
nCounter platform. Gene-specific mRNA abundance was 
determined for MRE11A, RAD50, NBN, ATM, ATR and 
PRKDC genes, housekeeping genes (β2-microglobulin, 
β-actin, and GAPDH). As recommended, positive control 
probes (6), geometric mean of housekeeping gene 
expression and negative control probes (8) were used to 
normalize the data.
Statistical Analyses
Patients with copy number gain and/or loss in each 
of the six DDR genes (MRE11A, RAD50, NBN, ATM, 
ATR and PRKDC) were compared to patients with copy 
neutral status for distribution of clinical variables of 
interest and treatment outcome. Chi-squared tests were 
used to compare the proportion of patients between CNA 
groups for clinical variables (PSA, T-category and GS). 
Association of CNA status of DDR-sensing genes with 
PGA was assessed by Student’s t-tests, and a multiple 
linear regression model was used to evaluate the effect 
of DDR genes on PGA adjusting for clinical variables 
(PSA, T-category and GS). Fisher’s exact test was used 
to assess mutual exclusivity and co-segregation of pairs 
of DDR-sensing genes. Student’s t-tests were calculated 
to determine the association between copy-number and 
mRNA abundance. Linear regression was used to describe 
the relationship between DDR genes mRNA abundance 
and clonogen radioresistance in vitro. 
The primary clinical outcome variable for both 
cohorts was time to biochemical recurrence, censored at 
five years. Cox proportional hazards regression models 
were used for univariate and multivariate models to assess 
the prognostic ability of DDR genes on biochemical 
relapse-free rate adjusting for known clinical prognostic 
factors. (PSA <10 vs. >=10; T1 vs. T2-T3; Gleason score 
5-6 vs. 7 or higher). The proportional hazards assumption 
was checked by investigating the Schoenfeld residuals. 
Five-year relapse-free rates were estimated using the 
Kaplan-Meier method. The additional utility of any copy 
number alteration relative to clinical parameters was 
described by the use of c-statistic, net reclassification 
index (NRI), and integrated discrimination improvement 
(IDI) [30]. The c-statistic presents the probability that a 
classification model gives a higher score to a patient that 
experiences a biochemical relapse by 5 years compared 
to a patient censored at five years. Thus, in the clinical 
setting, adding one biomarker to a validated clinical model 
may not change the classification of an event case to a non-
event case. NRI represents another informative measure of 
added value, which considers whether adding NBN to the 
basic clinical model increases the model’s risk scores for 
those patients that experienced a biochemical recurrence 
or decreases the risk scores for patients that were censored 
at 5 years, respectively. In turn, IDI calculates the 
improvement in sensitivity without changing specificity by 
calculating the difference in survival probability for each 
patient from the clinical model to the model with NBN 
gain incorporated.
All tests are two-sided and statistical significance 
was assessed using p<0.05. Multiple testing correction 
was applied where appropriate with the Bonferroni 
method, as specified in the text. All statistical analyses 
were performed using the open-source software R (v3.0-
1). The survival package (v2.37-4) was used to plot 
Kaplan-Meier curves and run Cox proportional-hazards 
regression models; the lattice (v0.20-15) and latticeExtra 
(v0.6-24) packages were used for data visualization.
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